2011, Number 98
<< Back Next >>
Rev Enfer Infec Pediatr 2011; 24.25 (98)
Metabolic disturbances secondary to antiretroviral therapy in HIV-infected children (first part)
Noguera-Julian A, Fortuny C
Language: Spanish
References: 8
Page: 35-37
PDF size: 180.14 Kb.
Text Extraction
No abstract
REFERENCES
• Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661-672.
• European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistr bution, and hyperlipidemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451.
• McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003;111:e275-281.
• PENTA Steering Committee, Welch S, Sharland M, et al. PENTA 2009 Guidelines for the Use of Antiretroviral Therapy in Paediatric HIV-1 Infection. HIV Med 2009;10:591-613.
• Recomendaciones CEVIHP/SEIP/AEP/PNS respecto al tratamiento antirretroviral en niños y adolescentes infectados por el Virus de la Inmunodeficiencia Humana (VIH). En: www.msc.es/ ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/ publicaciones.htm. Consultado el 7 de agosto de 2011.
• Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. August 16, 2010;1-219. En: http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Consultado el 7 de agosto de 2011.
• Vigano A, Aldrovandi GM, Giacomet V, Merlo M, Martelli L, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIVinfected children. Antivir Ther 2005;10:917-924.
• Wohl DA, Brown TT. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J Acquir Immune Defic Syndr.2008;49:S93-S100.
Full text